Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

UCSD Research May Lead to Targeted Treatment for Asthma Sufferers

30.11.2005


The bronchial tubes of a patient with severe asthma can become scarred due to repeated episodes of allergic inflammation in the airways. The scarring results in blocked airways, excessive production of mucus, and shortness of breath.



Researchers at the University of California, San Diego (UCSD) School of Medicine have discovered that when a single gene – IKK beta – is selectively inactivated in the membrane-lining cells of the bronchial tubes of mice that later inhale allergens, such scarring, mucus production and airway inflammation is significantly reduced.

David H. Broide, M.B.,Ch.B., Professor in UCSD’s Department of Medicine, and Michael Karin, Ph.D., Professor in UCSD’s Department of Pharmacology and the Laboratory of Gene Regulation and Signal Transduction, will publish their findings in the December 6 issue of the Proceedings of the National Academy of Sciences.


“This finding is significant because it suggests that if we can produce a drug that inhibits IKK beta – for example, a drug that is inhaled to target only the patient’s bronchial tubes and not their immune cells – then the scarring, inflammation, and mucus production in asthma could be significantly reduced,” said Broide.

IKK beta is a master regulator gene that is expressed in cells throughout the body including cells lining the bronchial tubes and immune cells, which are needed to fight infection. Through its effects on the transcription factor NF-kB, IKK beta also regulates the expression of many additional genes important to the induction of airway inflammation in asthma.

Using gene-targeting strategies, the UCSD team selectively inactivated the IKK beta gene only in the mouse airway membrane-lining cells, called epithelial cells, but not in other cells outside the airway that also express the gene, such as immune cells. The researchers were able to demonstrate that mice lacking the IKK beta gene in these lining cells had significantly less airway inflammation, mucus production and scarring of bronchial tubes after repeatedly inhaling an allergen.

The researchers set out to explore selective inactivation of IKK beta in the airway because blocking IKK beta throughout the body to prevent the damaging effects of asthma could also suppress the patient’s immune system, resulting in infections.

“An inhaled IKK beta antagonist could theoretically be designed that would not be absorbed into the blood stream, where it would affect the patient’s immune cell function. Such a selective targeting of the drug to the airway would be able to reduce airway inflammation, mucus production, and scarring of the bronchial tubes, with reduced potential for negative side effects.” said Broide.

While only about 10 percent of asthma patients have severe symptoms which lead to scarring of the bronchial tubes, new therapies to prevent scarring are needed, since these patients account for about half of the health costs associated with asthma. As patients with Chronic Obstructive Pulmonary Disease also suffer from mucus production and scarring of their lungs, an inhaled IKK beta antagonist could potentially prove beneficial in such patients.

This research was funded by a National Institutes of Health grant from the National Institute of Allergy and Infectious Diseases, and a grant from the Sandler Program for Asthma Research. Additional contributors to the paper include members of the Broide Laboratory, Jae Youn Cho, M.D., Ph,D,; Marina Miller, M.D., Ph.D.; Taylor Doherty, M.D.; Kirsti McElwain, B.S.; and Shauna McElwain, B.S., and Toby Lawrence, Ph.D. a visiting scientist in the Karin laboratory.

Debra Kain | EurekAlert!
Further information:
http://www.ucsd.edu

More articles from Health and Medicine:

nachricht Oxygen can wake up dormant bacteria for antibiotic attacks
08.12.2016 | Penn State

nachricht NTU scientists build new ultrasound device using 3-D printing technology
07.12.2016 | Nanyang Technological University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

Closing the carbon loop

08.12.2016 | Life Sciences

Applicability of dynamic facilitation theory to binary hard disk systems

08.12.2016 | Physics and Astronomy

Scientists track chemical and structural evolution of catalytic nanoparticles in 3-D

08.12.2016 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>